LAUSR

T he Dual Antiplatelet Therapy trial (1) appeared 4 years ago, but the decision to use dual antiplatelet therapy (DAPT) for 12 months or longer after drug-eluting stent (DES) implantation continues to be a topic of debate. To help clinicians, investigators created the DAPT score, a prediction rule designed to identify which patients might benefit from receiving DAPT for >1 year after DES implantation (2). When the DAPT score demonstrated modest accuracy in original cohorts (2), it was instantly included in the clinical guidelines by the writing committee of the American College of Cardiology/American Heart Association (3), but the writing committee for the European Society of Cardiology withheld judgment about the usefulness of the DAPT score until it could be independently validated (4).